Care pathways,
through the transition.

What a private clinic typically adds is consultation length, continuity of clinician, and a practice that centres the menopausal transition rather than fitting it into a 10-minute primary-care slot. What it does not add is a different clinical guideline — NICE NG23 governs UK menopause prescribing whether the consultation is NHS or private. The question worth asking before booking is whether the clinician holds British Menopause Society accreditation, what the fee structure covers (initial consultation, follow-up, prescription review), and whether the clinic prescribes within the NICE NG23 framework or extends beyond it. A clinic that prescribes well outside NICE NG23 is making a clinical choice that warrants a clear conversation about evidence and risk.

Both descriptions hold for parts of the UK telehealth market. Peppy (peppy.health) is the most-cited UK menopause telehealth platform; it is delivered primarily through employer benefits and partners with Wellbeing of Women, the UK women's health charity. Stella (joinstella.com) is direct-to-consumer subscription. The credibility test is the same one as for any clinic: who are the prescribing clinicians, what accreditation do they hold, and how does the prescribing scope read against NICE NG23. A telehealth platform with BMS-accredited clinicians prescribing within the NICE NG23 framework is a clinical service delivered through a different channel; one without that backing is a content product with a consultation attached.

The Collaborative Group on Hormonal Factors in Breast Cancer 2019 meta-analysis in The Lancet, drawing on 108,647 postmenopausal breast cancer cases, reports that current oestrogen-progestagen users carry a relative risk of 1.60 in years 1–4 and 2.08 in years 5–14; oestrogen-only preparations carry smaller relative risks (1.17, 1.33); vaginal oestrogens were not associated with excess risk. The population-level framing in the paper: 5 years of oestrogen-plus-daily-progestagen MHT starting at age 50 corresponds to roughly one extra breast cancer per 50 users by age 69. This is a quantified trade-off, not a verdict. The framing for a reader booking a consultation is that the right place to read this number against your own family history, baseline risk and symptom burden is with a BMS-accredited clinician — not with a website.

Because this is the page on the site where the answer is not a Solgar supplement and is also not a treatment recommendation. There is no supplement that replaces a clinical consultation, a NICE-aligned prescribing decision, or the longitudinal relationship a reader builds with a clinician. HerStack is published by Suggestic, a digital nutrition company; we picked Solgar UK as the reference brand for the supplement clusters where formulation matters. On this cluster the criteria that matter are different — UK availability, BMS-accredited clinicians, transparent fees, NICE NG23-aligned prescribing scope, and an honest framing of what each pathway can and cannot offer. The cards below describe options to consider and questions to ask. The clinical decision is yours to make with a clinician.

We review each cluster page against new evidence quarterly, and update the page header date when we make a substantive change. The pathway cards below carry their own last-reviewed date so you can see when the provider fee structures and the regulatory framing were last checked.